logo

La Jolla Pharmaceutical Co (LJPC)



Trade LJPC now with
  Date
  Headline
4/3/2020 8:39:28 AM La Jolla Provide GIAPREZA For Named Patient Emergency Use In Patients With Septic Shock Due To COVID-19
1/9/2020 8:13:28 AM La Jolla Pharmaceutical Three-month Preliminary GIAPREZA Net Sales $7.2 Mln
11/25/2019 8:39:57 AM La Jolla To Reassess Continued Development Of LJPC-401
7/23/2019 9:08:07 AM La Jolla Gets Orphan Designation From FDA For LJPC-0118 For Malaria Treatment
3/11/2019 7:42:20 AM La Jolla Pharmaceutical Appoints Darryl Wellinghoff As Chief Commercial Officer
6/25/2018 9:02:56 AM La Jolla Nnounces European Medicines Agency Validation Of Marketing Authorisation Application For GIAPREZA
5/10/2018 4:51:15 PM La Jolla Q1 Net Loss $50.5 Mln Or $2.22 Per Share
5/10/2018 4:46:35 PM La Jolla Closes $125 Mln Royalty Financing Agreement With HealthCare Royalty Partners
3/15/2018 8:04:26 AM La Jolla Pharmaceutical Prices Public Offering Of 3.40 Mln Shares At $29.50 Per Share
3/14/2018 4:02:07 PM La Jolla Pharmaceutical Company Announces $100 Mln Public Offering Of Common Stock
2/25/2018 9:31:43 AM La Jolla Pharma: GIAPREZA Significantly Improved Survival Of Patients With High APACHE II Scores In ATHOS-3 Study